iBio, Inc. Common Stock (IBIO)vsRoyalty Pharma Plc (RPRX)
IBIO
iBio, Inc. Common Stock
$1.82
-5.70%
HEALTHCARE · Cap: $90.42M
RPRX
Royalty Pharma Plc
$55.02
-0.11%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 813407% more annual revenue ($2.44B vs $300,000). RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
IBIO
Avoid29
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IBIO.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IBIO
The strongest argument for IBIO centers on Price/Book, Debt/Equity. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : IBIO
The primary concerns for IBIO are EPS Growth, Market Cap, Profit Margin.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
IBIO profiles as a value stock while RPRX is a mature play — different risk/reward profiles.
IBIO carries more volatility with a beta of 1.24 — expect wider price swings.
IBIO is growing revenue faster at 14.3% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 29/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
iBio, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. The company is headquartered in New York, New York.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?